JP6706617B2 - 抗プロ／潜在型−ミオスタチン抗体およびその使用 - Google Patents

抗プロ／潜在型−ミオスタチン抗体およびその使用 Download PDF

Info

Publication number
JP6706617B2
JP6706617B2 JP2017523975A JP2017523975A JP6706617B2 JP 6706617 B2 JP6706617 B2 JP 6706617B2 JP 2017523975 A JP2017523975 A JP 2017523975A JP 2017523975 A JP2017523975 A JP 2017523975A JP 6706617 B2 JP6706617 B2 JP 6706617B2
Authority
JP
Japan
Prior art keywords
antibody
seq
pro
myostatin
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017523975A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017536354A (ja
JP2017536354A5 (enExample
Inventor
ミッシェル ストラウブ，
ミッシェル ストラウブ，
ドン ユン リー，
ドン ユン リー，
ウィリアム ケー． マコノヒー，
ウィリアム ケー． マコノヒー，
キャサリーン ジェーン ターナー，
キャサリーン ジェーン ターナー，
ナゲッシュ ケー． マハンサッパ，
ナゲッシュ ケー． マハンサッパ，
ジャスティン ダブリュー． ジャクソン，
ジャスティン ダブリュー． ジャクソン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scholar Rock Inc
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Publication of JP2017536354A publication Critical patent/JP2017536354A/ja
Publication of JP2017536354A5 publication Critical patent/JP2017536354A5/ja
Application granted granted Critical
Publication of JP6706617B2 publication Critical patent/JP6706617B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017523975A 2014-11-06 2015-11-06 抗プロ／潜在型−ミオスタチン抗体およびその使用 Active JP6706617B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201462076230P 2014-11-06 2014-11-06
US62/076,230 2014-11-06
US201562100361P 2015-01-06 2015-01-06
US62/100,361 2015-01-06
US201562187348P 2015-07-01 2015-07-01
US62/187,348 2015-07-01
US201562219094P 2015-09-15 2015-09-15
US62/219,094 2015-09-15
PCT/US2015/059468 WO2016073853A1 (en) 2014-11-06 2015-11-06 Anti-pro/latent-myostatin antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020085618A Division JP2020127430A (ja) 2014-11-06 2020-05-15 抗プロ／潜在型−ミオスタチン抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2017536354A JP2017536354A (ja) 2017-12-07
JP2017536354A5 JP2017536354A5 (enExample) 2018-12-13
JP6706617B2 true JP6706617B2 (ja) 2020-06-10

Family

ID=55909861

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017523975A Active JP6706617B2 (ja) 2014-11-06 2015-11-06 抗プロ／潜在型−ミオスタチン抗体およびその使用
JP2020085618A Withdrawn JP2020127430A (ja) 2014-11-06 2020-05-15 抗プロ／潜在型−ミオスタチン抗体およびその使用
JP2022130847A Pending JP2022166238A (ja) 2014-11-06 2022-08-19 抗プロ／潜在型－ミオスタチン抗体およびその使用
JP2024077058A Pending JP2024109663A (ja) 2014-11-06 2024-05-10 抗プロ／潜在型－ミオスタチン抗体およびその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020085618A Withdrawn JP2020127430A (ja) 2014-11-06 2020-05-15 抗プロ／潜在型−ミオスタチン抗体およびその使用
JP2022130847A Pending JP2022166238A (ja) 2014-11-06 2022-08-19 抗プロ／潜在型－ミオスタチン抗体およびその使用
JP2024077058A Pending JP2024109663A (ja) 2014-11-06 2024-05-10 抗プロ／潜在型－ミオスタチン抗体およびその使用

Country Status (7)

Country Link
US (4) US10307480B2 (enExample)
EP (1) EP3215175A4 (enExample)
JP (4) JP6706617B2 (enExample)
AU (3) AU2015342936B2 (enExample)
CA (1) CA3005158A1 (enExample)
HK (1) HK1243940A1 (enExample)
WO (1) WO2016073853A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018527000A (ja) * 2015-09-15 2018-09-20 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 抗プロ／潜在型ミオスタチン抗体およびその使用

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2568436T3 (es) 2006-03-31 2016-04-29 Chugai Seiyaku Kabushiki Kaisha Procedimiento para controlar la farmacocinética en sangre de anticuerpos
BRPI0817294A2 (pt) 2007-09-26 2015-03-17 Chugai Pharmaceutical Co Ltd Método de modificação do ponto isoelétrico de anticorpo via substituição de aminoácido em cdr.
EP3056513A1 (en) 2008-04-11 2016-08-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
KR102568454B1 (ko) 2010-11-30 2023-08-18 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
EP2889376A4 (en) 2012-08-24 2016-11-02 Chugai Pharmaceutical Co Ltd MOUSE FC RII SPECIFIC FC ANTIBODY
TW202237660A (zh) 2012-08-24 2022-10-01 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
WO2014163101A1 (ja) 2013-04-02 2014-10-09 中外製薬株式会社 Ｆｃ領域改変体
PL2981822T3 (pl) * 2013-05-06 2021-07-12 Scholar Rock, Inc. Kompozycje i sposoby modulacji czynnika wzrostu
US10307480B2 (en) 2014-11-06 2019-06-04 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
EP4600372A3 (en) 2014-12-19 2025-11-19 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
PT3653221T (pt) 2015-02-19 2022-11-08 Compugen Ltd Anticorpos anti-pvrig e métodos de utilização
KR101820637B1 (ko) * 2015-12-18 2018-01-19 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE
CN109071645A (zh) 2016-01-08 2018-12-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
DK3368069T3 (da) * 2016-06-13 2020-11-02 Scholar Rock Inc Anvendelse af myostatininhibitorer og kombinationsterapier
CN109311969B (zh) * 2016-06-17 2022-09-27 中外制药株式会社 抗-肌肉生长抑制因子抗体及使用方法
US11053308B2 (en) 2016-08-05 2021-07-06 Chugai Seiyaku Kabushiki Kaisha Method for treating IL-8-related diseases
DK3565592T5 (da) * 2017-01-06 2024-09-02 Scholar Rock Inc Behandling af stofskiftesygdomme ved inhibering af myostatinaktivering
PT3565592T (pt) 2017-01-06 2023-05-31 Scholar Rock Inc Tratamento de doenças metabólicas através da inibição da ativação da miostatina
MA52165A (fr) 2018-07-11 2021-06-02 Scholar Rock Inc Inhibiteurs sélectifs de l'isoforme tgfbeta1 et utilisation associée
CN112996535A (zh) 2018-07-11 2021-06-18 供石公司 高亲和性、亚型选择性TGFβ1抑制剂及其用途
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
JP2024524159A (ja) 2021-06-23 2024-07-05 スカラー ロック インコーポレイテッド 代謝障害の治療における使用のためのｇｌｐ－１経路活性化剤と組み合わせたミオスタチン経路阻害剤
WO2023079430A1 (en) * 2021-11-02 2023-05-11 Pfizer Inc. Methods of treating mitochondrial myopathies using anti-gdf15 antibodies
CN114891101B (zh) * 2021-12-02 2023-06-16 吉林省农业科学院 一种牛肌肉生长抑制素蛋白单克隆抗体及其应用
TW202430247A (zh) 2022-12-22 2024-08-01 美商供石公司 肌肉生長抑制素活化之選擇性及強效抑制劑
EP4676954A1 (en) 2023-03-07 2026-01-14 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer
WO2025245160A1 (en) 2024-05-21 2025-11-27 Scholar Rock, Inc. Myostatin-selective inhibitors for treating metabolic disorders

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7566768B1 (en) 1995-10-26 2009-07-28 The Johns Hopkins University School Of Medicine Promyostatin peptides and methods of using same
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
DE69432815T2 (de) 1993-03-19 2003-12-11 The Johns Hopkins University School Of Medicine, Baltimore Wachstumsfaktor-8
US20030167492A1 (en) 1994-07-08 2003-09-04 Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same
CA2194660C (en) 1994-07-08 2009-09-29 Se-Jin Lee Growth differentiation factor-11
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
FR2804102B1 (fr) 2000-01-26 2002-08-16 Rhodia Terres Rares Dispersion colloidale aqueuse d'un compose de cerium et d'au moins un autre element choisi parmi les terres rares, des metaux de transition, l'aluminium, le gallium et le zirconium, procede de preparation et utilisation
KR20020090211A (ko) 2000-01-28 2002-11-30 노보 노르디스크 에이/에스 알키닐 치환된 프로피온산 유도체 및 당뇨병 및 비만에대한 그것의 사용
PT2275449T (pt) * 2000-06-16 2016-12-27 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
AU2011244851A1 (en) * 2000-07-27 2011-11-24 The John Hopkins University School Of Medicine Promyostatin peptides and methods of using same
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
ES2288900T3 (es) 2001-10-05 2008-02-01 Affimed Therapeutics Ag Anticuerpo de origen humano para inhibir la agregacion de trombocitos.
US8455627B2 (en) * 2001-10-05 2013-06-04 Affimed Therapeutics, Ag Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa
CA2493067A1 (en) 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. Treatment of tnf.alpha. related disorders
EP2192129A1 (en) 2002-09-16 2010-06-02 Johns Hopkins University Metalloprotease activation of myostatin, and methods of modulating myostatin activity
AR047392A1 (es) * 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US7285269B2 (en) * 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
KR20160045936A (ko) 2002-12-20 2016-04-27 암겐 인코포레이티드 미오스타틴을 저해하는 결합제
UA93855C2 (ru) * 2003-12-31 2011-03-25 Шеринг-Плау Лтд. Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе
JP2007526337A (ja) 2004-03-02 2007-09-13 アクセルロン ファーマ インコーポレーテッド Ａｌｋ７およびミオスタチン阻害剤ならびにその使用
MXPA06010929A (es) 2004-03-23 2007-01-16 Lilly Co Eli Anticuerpos anti-miostatina.
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
KR20070026650A (ko) 2004-05-27 2007-03-08 악셀레론 파마 인코포레이티드 케르베루스/코코 유도체 및 그의 용도
AU2005271523B2 (en) 2004-08-03 2011-09-15 Dyax Corp. hk1-binding proteins
AU2006208286A1 (en) * 2005-01-26 2006-08-03 Amgen Fremont Inc. Antibodies against interleukin-1 beta
US20060216279A1 (en) 2005-03-22 2006-09-28 Glass David J Myostatin inhibiting fusion polypeptides and therapeutic methods thereof
EA015534B1 (ru) 2005-04-25 2011-08-30 Пфайзер Инк. Антитела к миостатину и способы их применения
HUE025240T2 (en) 2005-08-19 2016-03-29 Wyeth Llc Anti-GDF-8 antagonist antibodies and their use in the treatment of ALS and other disorders associated with GDF-8
US7635760B2 (en) 2005-10-06 2009-12-22 Eli Lilly And Company Anti-myostatin antibodies
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
WO2007061995A2 (en) * 2005-11-21 2007-05-31 Novartis Ag Biomarkers for statin-induced myopathy or rhabdomyolysis
US8097596B2 (en) 2006-06-30 2012-01-17 Lakewood-Amedex, Inc. Compositions and methods for the treatment of muscle wasting
DK2054434T3 (en) * 2006-08-03 2017-07-03 Myostin Therapeutics Pty Ltd Myostatin antagonists
KR101123531B1 (ko) 2006-09-05 2012-04-20 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
ES2569365T3 (es) 2006-11-29 2016-05-10 Nationwide Children's Hospital Inhibición de miostatina para la potenciación de músculo y/o la mejora de la función muscular
JP5670179B2 (ja) 2007-03-30 2015-02-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 負の光学的分散を有する複屈折層
EP2162152A2 (en) * 2007-06-01 2010-03-17 Biogen Idec MA, Inc. Cripto binding molecules
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
AU2009246687B2 (en) * 2008-05-13 2012-08-09 Irm Llc Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
TW201029662A (en) * 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
WO2010099219A2 (en) 2009-02-24 2010-09-02 The Salk Institute For Biological Studies Designer ligands of tgf-beta superfamily
US20120022057A1 (en) * 2009-03-18 2012-01-26 Schering Corporation Bicyclic compounds as inhibitors of diacyglycerol acyltransferase
SG174273A1 (en) 2009-04-27 2011-10-28 Novartis Ag Compositions and methods for increasing muscle growth
EP2440576A4 (en) 2009-06-08 2013-11-20 Acceleron Pharma Inc PROCESS FOR INCREASING THE NUMBER OF THERMOUS ADIPOCYTES
US8945511B2 (en) 2009-06-25 2015-02-03 Paul Weinberger Sensitive methods for detecting the presence of cancer associated with the over-expression of galectin-3 using biomarkers derived from galectin-3
EP2483300A4 (en) 2009-10-01 2013-02-27 Covita Ltd SYNTHETIC PEPTIDE ANTAGONISTS OF MYOSTATIN
EP3511342B1 (en) 2010-03-10 2024-01-17 Genmab A/S Monoclonal antibodies against c-met
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
US8999343B2 (en) * 2010-08-16 2015-04-07 Amgen Inc. Antibodies that bind myostatin, compositions and methods
WO2013071056A2 (en) 2011-11-11 2013-05-16 Duke University Combination drug therapy for the treatment of solid tumors
HUE038570T2 (hu) * 2011-11-14 2018-10-29 Regeneron Pharma Készítmények és eljárások izomtömeg és izomerõ növelésére GDF8 és/vagy aktivin A specifikus antagonizálásával
US20130178454A1 (en) 2011-11-17 2013-07-11 Shalender Bhasin Combination of testosterone and ornithine decarboxylase (odc) inhibitors
WO2013148284A1 (en) 2012-03-29 2013-10-03 Genentech, Inc. Antibodies that bind to a pcsk9 cleavage site and methods of use
WO2013165972A2 (en) 2012-04-30 2013-11-07 Cell Signaling Technology, Inc. Anti-hepatitis b virus antibodies and use thereof
KR101704893B1 (ko) 2012-06-15 2017-02-08 화이자 인코포레이티드 Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도
MX388059B (es) * 2012-11-06 2025-03-19 Scholar Rock Inc Composiciones y metodos para modular la comunicacion celular.
PL2981822T3 (pl) 2013-05-06 2021-07-12 Scholar Rock, Inc. Kompozycje i sposoby modulacji czynnika wzrostu
EP2853898B1 (en) * 2013-09-27 2017-01-04 Medizinische Hochschule Hannover Analysis of myostatin in serum
CA2929574A1 (en) 2013-11-11 2015-05-14 Sirna Therapeutics, Inc. Systemic delivery of myostatin short interfering nucleic acids (sina) conjugated to a lipophilic moiety
WO2015195094A1 (en) 2014-06-17 2015-12-23 Ember Therapeutics, Inc. Anti-activin and nati-myostatin antibodies and methods of using the same
WO2016073879A2 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related antibodies and uses thereof
US10307480B2 (en) 2014-11-06 2019-06-04 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
EP4600372A3 (en) * 2014-12-19 2025-11-19 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
EA201792298A1 (ru) 2015-04-15 2018-04-30 Регенерон Фармасьютикалз, Инк. Способы увеличения силы и функциональности с помощью ингибиторов gdf8
HRP20250666T1 (hr) 2015-09-15 2025-08-01 Scholar Rock, Inc. Anti-pro/latentna miostatinska protutijela i njihove uporabe
CN109071645A (zh) 2016-01-08 2018-12-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
DK3368069T3 (da) 2016-06-13 2020-11-02 Scholar Rock Inc Anvendelse af myostatininhibitorer og kombinationsterapier
JOP20190152A1 (ar) 2016-12-21 2019-06-20 Novartis Ag مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة
DK3565592T5 (da) 2017-01-06 2024-09-02 Scholar Rock Inc Behandling af stofskiftesygdomme ved inhibering af myostatinaktivering

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018527000A (ja) * 2015-09-15 2018-09-20 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 抗プロ／潜在型ミオスタチン抗体およびその使用
JP7107836B2 (ja) 2015-09-15 2022-07-27 スカラー ロック インコーポレイテッド 抗プロ／潜在型ミオスタチン抗体およびその使用

Also Published As

Publication number Publication date
WO2016073853A1 (en) 2016-05-12
JP2022166238A (ja) 2022-11-01
HK1243940A1 (zh) 2018-07-27
US11135291B2 (en) 2021-10-05
US20220152200A1 (en) 2022-05-19
JP2017536354A (ja) 2017-12-07
EP3215175A4 (en) 2018-06-27
AU2015342936A1 (en) 2017-06-01
US20240374718A1 (en) 2024-11-14
AU2015342936B2 (en) 2020-10-08
AU2020294193B2 (en) 2024-02-15
JP2024109663A (ja) 2024-08-14
US20190365891A1 (en) 2019-12-05
US20170333558A1 (en) 2017-11-23
CA3005158A1 (en) 2016-05-12
US11925683B2 (en) 2024-03-12
EP3215175A1 (en) 2017-09-13
AU2020294193A1 (en) 2021-01-28
AU2024203178A1 (en) 2024-06-06
US10307480B2 (en) 2019-06-04
JP2020127430A (ja) 2020-08-27

Similar Documents

Publication Publication Date Title
JP7785107B2 (ja) 抗プロ／潜在型ミオスタチン抗体およびその使用
JP6706617B2 (ja) 抗プロ／潜在型−ミオスタチン抗体およびその使用
HK40064070B (en) Anti-pro/latent-myostatin antibodies and uses thereof
HK40117719A (en) Anti-pro/latent-myostatin antibodies and uses thereof
HK40064070A (en) Anti-pro/latent-myostatin antibodies and uses thereof
HK1258267B (en) Anti-pro/latent-myostatin antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190531

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20190613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190531

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200403

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200427

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200518

R150 Certificate of patent or registration of utility model

Ref document number: 6706617

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250